Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. <li /> GLOW2 study design mirrors GLOW1 study, ...

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and ...

The company will publish its Full-Year 2024 financial results on March 26, 2025. On the reporting date, BioVersys will issue a press release at 7:00 AM CET.

A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...

Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therapeutic, EV25. The study will provide safety and ...

In this edition of “Rising High,” The Fly conducted an exclusive interview with Jared Stanley, Chief Executive Officer, and Joel Stanley, ...

Enliven Therapeutics increased its research and development spending in the fourth quarter of fiscal 2024 as several drug ...

From landmark indies to star-studded blockbusters, Steven Soderbergh has restlessly forged an eclectic body of work.

A deep-learning algorithm has enabled ultra-low dose CT scans to diagnose pneumonia with only 2% of the radiation of standard ...

Throughout the year, IndieWire runs a survey for cinematographers with films playing at major festivals around the world to ...

OnKure's drug candidate pipeline is highlighted by OKI-219, a selective PI3K alpha H1047R inhibitor for the treatment of certain types of breast cancer that began clinical trials in February 2024.

What is the KMTC online application process like? Read on to discover the requirements, processes, and guidelines for ...